No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: No P/S history yet
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The closing share price for PDS Biotechnology Corporation (PDSB) stock was $0.21 for Friday, August 28, 2026, down 3.21% on the day.
Longer view (total return, dividends reinvested): past 12 months -83.0% · 3-year avg -67.9%/yr · 5-year avg -57.0%/yr
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer.
Biotechnology · Princeton, NJ
Next Earnings Date
Nov 12, 2026
73 days away
EPS Estimate
-0.11
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.13
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PDSB | $11.79M | $0.21 | -3.21% | -83.01% | -57.05% | -49.05% | N/A |
| 2SI | $438.82M | $21.16 | -0.52% | +42.91% | N/A | N/A | vs PDSB |
| 3NRC | $492.43M | $21.85 | -0.73% | +54.42% | -14.85% | +4.82% | vs PDSB |
| 4TDOC | $1.18B | $6.50 | +2.20% | -17.63% | -46.08% | -9.35% | vs PDSB |
| 5XRAY | $2.23B | $11.12 | +0.72% | -20.27% | -27.58% | -14.49% | vs PDSB |
| 6TMDX | $3.06B | $88.43 | -3.62% | -24.26% | +22.62% | N/A | vs PDSB |
next-FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$5.75
+2626.4% upside
Low
$4.50
Current
$0.21
High
$7.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.11 | $-0.11 | $-0.10 | 1 |
| Quarter ending Dec 2026 | $-0.08 | $-0.07 | $-0.06 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.46 | $-0.45 | $-0.44 | 1 |
| FY 2027 | $-0.36 | $-0.33 | $-0.30 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $11.25M | $11.25M | $11.25M | 2 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates.
| $23.15M |
| $23.15M |
| $23.15M |
| 2 |
